Abstracts Archive - Page 1754 of 2425 - ACR Meeting Abstracts

Abstract Number: 970 • 2015 ACR/ARHP Annual Meeting
Efficacy and Safety of Sarilumab in Combination with Csdmards in Patients with Active Rheumatoid Arthritis Who Were Inadequate Responders or Intolerant of Anti–TNF-Î± Therapy: Results from a Phase 3 Study
Roy Fleischmann¹, Geraldo Castelar-Pinheiro², Jan Brzezicki³, Pawel Hrycaj⁴, Yong Lin⁵, Janet van Adelsberg⁶, Neil Graham⁷, Hubert van Hoogstraten⁵, Deborah Bauer⁵ and Gerd Burmester⁸, ¹University of Texas Southwestern Medical Center, Dallas, TX, ²Discipline of Rheumatology, Rio de Janeiro State University, Rio de Janeiro, Brazil, ³Centrum Kliniczno-Badawcze, Elblag, Poland, ⁴Poznan University of Medical Sciences, Poznan, Poland, ⁵Sanofi, Bridgewater, NJ, ⁶Clinical Science, Regeneron Pharmaceutials, Inc., Tarrytown, NY, ⁷Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁸Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany
Background/Purpose: The investigational agent sarilumab is a human mAb directed against the IL-6 receptor. The phase 3 MOBILITY study (NCT01061736) evaluated the efficacy and safety…
Abstract Number: 971 • 2015 ACR/ARHP Annual Meeting
Safety and Tolerability of Subcutaneous Sarilumab Compared to Intravenous Tocilizumab in Patients with RA
Paul Emery¹, Juan Rondon², Anju Garg³, Hubert van Hoogstraten³, Neil Graham⁴, Ming Liu⁵, Janie Parrino⁶, Alberto J. Spindler⁷ and Nancy Liu⁵, ¹Division of Rheumatic and Musculoskeletal Disease, University of Leeds, Leeds, United Kingdom, ²Elite Research Institute, Miami, FL, ³Sanofi, Bridgewater, NJ, ⁴Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁵Regeneron Pharmaceuticals, Tarrytown, NY, ⁶Merck & Co., Inc., Whitehouse Station, NJ, ⁷Rheumatology, Hospital Padilla, Tucuman, Argentina
Background/Purpose: The investigational drug sarilumab is a human mAb directed against the IL-6 receptor. In previous studies, sarilumab + MTX demonstrated efficacy in patients (pts)…
Abstract Number: 972 • 2015 ACR/ARHP Annual Meeting
A Phase 2b Study Evaluating the Efficacy and Safety of Subcutaneously Administered Tregalizumab in Subjects with Active Rheumatoid Arthritis (RA) Despite Treatment with Methotrexate (MTX)
Ronald F. van Vollenhoven¹, Edward C. Keystone², Vibeke Strand³, Cesar Pacheco-Tena⁴, Jiri Vencovsky⁵, Frank Behrens⁶, Daniela Zipp⁷, Faiza Rharbaoui⁸, Ralf Wolter⁹, Rolf-Dietrich Tiemann¹⁰, Luise Knierim¹¹, Rainer Schmeidl¹¹, Xuefei Zhou¹², Silke Aigner^8,13, Benjamin Daelken¹⁴ and Andrea Wartenberg-Demand^8,12, ¹Department of Medicine, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden, ²Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ³Biopharmaceutical Consultant, Portola Valley, CA, ⁴Universidad Autónoma de Chihuahua, Chihuahua, Mexico, ⁵Institute of Rheumatology, Prague, Czech Republic, ⁶CIRI/Rheumatology & Fraunhofer TMP, Goethe University, Frankfurt, Germany, ⁷Landseinerstr 5, Biotest AG, Dreieich, Germany, ⁸Biotest AG, Dreieich, Germany, ⁹Corporate Clinical Research, L, Biotest AG, Dreieich, Germany, ¹⁰Data Management and Outsourcing, Biotest AG, Dreieich, Germany, ¹¹Cooperate Drug Safety, Biotest AG, Dreieich, Germany, ¹²Cooperate Clinical Research, Biotest AG, Dreieich, Germany, ¹³Landsteinerstrasse 5, Biotest AG, Dreieich, Germany, ¹⁴Project Managerment Office, Biotest Pharmaceuticals Corporation, Boca Raton, FL
Background/Purpose: In autoimmune diseases reduced numbers and functional impairment of regulatory T cells (Tregs) have been observed (1). Tregalizumab (BT-061) is a humanized, anti-CD4 mAb,…
Abstract Number: 973 • 2015 ACR/ARHP Annual Meeting
The Effect of TNF Inhibitor Treatment on Occurrence of Anterior Uveitis in Ankylosing Spondylitis: Results from the Swedish Biologics Register
Elisabeth Lie^1,2, Ulf Lindström², Tatiana Zverkova-Sandström², Inge C Olsen¹, Helena Forsblad-d'Elia³, Johan Askling⁴, Lars Erik Kristensen^5,6 and Lennart TH Jacobsson², ¹Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Dept. of Rheumatology and Inflammation Research, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden, ³Departments of Public Health and Clinical Medicine, Rheumatology, Umeå University, Umeå, Sweden, ⁴Clinical Epidemiology Unit & Rheumatology Unit, Dept. of Medicine, Karolinska Institutet, Stockholm, Sweden, ⁵Musculoskeletal Statistics Unit, The Parker Institute, Dept. of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen, Denmark, ⁶Section of Rheumatology, Department of Clinical Sciences, Lund University, Malmö, Sweden
Background/Purpose: Anterior uveitis is a relatively frequent extra-articular manifestation in ankylosing spondylitis (AS), with a prevalence of 25.8% in a recent meta-analysis. TNF inhibitor (TNFi)…
Abstract Number: 974 • 2015 ACR/ARHP Annual Meeting
Secukinumab Significantly Improves Signs and Symptoms of Active Ankylosing Spondylitis: 52-Week Results from a Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial with Subcutaneous Loading and Maintenance Dosing
Juergen Braun¹, Atul A. Deodhar², Joachim Sieper³, Maxime Dougados⁴, Brian Porter⁵, Mats Andersson⁶ and Hanno Richards⁶, ¹Rheumazentrum Ruhrgebiet, Herne, Germany, ²Division of Arthritis & Rheumatic Diseases, Oregon Health & Science University, Portland, OR, ³University Clinic Benjamin Franklin, Berlin, Germany, ⁴Université Paris René Descartes and Hôpital Cochin, Paris, France, ⁵Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁶Novartis Pharma AG, Basel, Switzerland
Background/Purpose: In MEASURE 2 (NCT01649375), subcutaneous (s.c.) secukinumab, an anti–interleukin-17A antibody, improved the signs and symptoms of ankylosing spondylitis (AS) through 16 weeks (wks) of…
Abstract Number: 975 • 2015 ACR/ARHP Annual Meeting
The Effect of TNF Inhibition on Radiographic Progression in Ankylosing Spondylitis: An Observational Cohort Study of 374 Patients
Walter Maksymowych¹, Yufei Zheng², Stephanie Wichuk¹, Sasha Bernatsky³, Praveena Chiowchanwisawakit⁴ and Robert G Lambert⁵, ¹Medicine, Medicine, University of Alberta, Edmonton, AB, Canada, ²Alberta Institute of Health Economics, Edmonton, AB, Canada, ³Rheum/Clin. Epid., McGill MUHC/RVH, Montreal, QC, Canada, ⁴Rheumatology, Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand, ⁵Radiology, Radiology, University of Alberta, Edmonton, AB, Canada
Background/Purpose: An analysis of radiographic progression in an observational cohort has suggested that anti-TNF therapy lessens radiographic progression, especially when treatment is introduced within 5…
Abstract Number: 976 • 2015 ACR/ARHP Annual Meeting
The Reason of Discontinuation of a First TNF Inhibitor Affects Drug Retention of a Second Anti-TNF Agent in Axial Spondyloarthritis
Adrian Ciurea¹, Pascale Exer², Ulrich Weber^3,4, Giorgio Tamborrini⁵, Beate Steininger¹, Rudolf O. Kissling⁶, Jürg Bernhard⁷ and Almut Scherer⁸, ¹Rheumatology, University Hospital Zurich, Zurich, Switzerland, ²Private rheumatology practice, Basel, Switzerland, ³Institute of Regional Health Research, University of Southern Denmark, Odense, Denmark, ⁴Department of Research, King Christian 10th Hospital for Rheumatic Diseases, Graasten, Denmark, ⁵Department of Rheumatology, University Hospital, Zurich, Switzerland, ⁶Division of Rheumatology, Balgrist University Hospital, Zurich, Switzerland, ⁷Rheumatology and Rehabilitation, Bürgerspital Solothurn, Solothurn, Switzerland, ⁸SCQM Foundation, Zurich, Switzerland
Background/Purpose: Conflicting results have been demonstrated in axial spondyloarthritis (axSpA) with regard to whether effectiveness of a second (2°) TNFi depends on the reason of…
Abstract Number: 977 • 2015 ACR/ARHP Annual Meeting
A Randomized, Double-Blind, Active- and Placebo-Controlled Phase 3 Study of Efficacy and Safety of Ixekizumab, Adalimumab, and Placebo Therapy in Patients Naïve to Biologic Disease Modifying Anti-Rheumatic Drugs with Active Psoriatic Arthritis
Philip J. Mease¹, Désirée van der Heijde², Christopher T. Ritchlin³, Raquel Cuchacovich^4,5, Catherine L. Shuler⁵, Chin H. Lee⁵, Suvajit Samanta⁵, Chen-Yen Lin⁵, Dafna D. Gladman⁶ and Harald Vangerow⁵, ¹Department of Rheumatology, Swedish Medical Center and University of Washington, Seattle, WA, ²Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands, Leiden, Netherlands, ³Allergy Immunology & Rheumatology, University of Rochester Medical Center, Rochester, NY, ⁴School of Medicine, Rheumatology Division, Indiana University, Indianapolis, IN, ⁵Eli Lilly and Company, Indianapolis, IN, ⁶Department of Medicine, Division of Rheumatology, University of Toronto, Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis (PsA) is a chronic immune-mediated inflammatory disease associated with psoriasis which includes peripheral arthritis, enthesitis, dactylitis, and spondylitis manifestations. Ixekizumab, under investigation…
Abstract Number: 978 • 2015 ACR/ARHP Annual Meeting
Continuous Versus on Demand Treatment of Ankylosing Spondylitis with Diclofenac over 2 Years Does Not Prevent Radiographic Progression of the Spine: Results from a Randomized Prospective Multi-Center Trial
Joachim Sieper¹, Joachim Listing², Denis Poddubnyy¹, In-Ho Song^1,3, Kay-Geert Hermann¹, Johanna Callhoff², Jürgen Braun⁴ and Martin Rudwaleit^1,5, ¹Charité Universitätsmedizin Berlin, Berlin, Germany, ²German Rheumatism Research Centre, Berlin, Germany, ³Abbvie, Chicago, IL, ⁴Rheumazentrum Ruhrgebiet, Herne, Germany, ⁵Klinikum Bielefeld, Bielefeld, Germany
Background/Purpose: Previously it was shown that non-steroidal antiinflammatory drugs (NSAIDs) given continuously reduce radiographic progression compared to an on demand therapy over 2 years in…
Abstract Number: 979 • 2015 ACR/ARHP Annual Meeting
HLA Class I Genes As Susceptibility Markers of Psoriatic Arthritis in Patients with Psoriasis – a Meta-Analysis
Lihi Eder¹, Fatima Abji², Cheryl Rosen³, Muhammad Haroon⁴, Vinod Chandran¹, Rubén Queiro⁵, Shelley Bull⁶, Richard J. Cook⁷, Proton Rahman⁸, Robert Winchester⁹, Oliver FitzGerald¹⁰ and Dafna D. Gladman¹, ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Dermatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴Kerry General Hospital, Tralee, Ireland, ⁵Rheumatology Service, Hospital Universitario Central de Asturias, Oviedo, Spain, ⁶School of Public Health, Mount Sinai Hospital, Toronto, ON, Canada, ⁷Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada, ⁸Computer Sciences, Memorial University of Newfoundland, St. John's, NF, Canada, ⁹Columbia University, New York, NY, ¹⁰Department of Rheumatology, St Vincent's University Hospital, Dublin, Ireland
Background/Purpose: Genes that differentiate patients with psoriatic arthritis (PsA) from those with psoriasis alone may serve as markers for the development of PsA in psoriasis…
Abstract Number: 980 • 2015 ACR/ARHP Annual Meeting
Association of Platelet Endothelial Cell Adhesion Molecule-1 and ß1 Integrin Gene Polymorphisms with Uveitis Development in Ankylosing Spondylitis
Seung-Cheol Shim¹, In-Seol Yoo², Su-Jin Yoo¹, Young Kim¹, Mi-Kyoung Lim³, Dong-Hyuk Sheen⁴ and Jinhyun Kim⁵, ¹Rheumatology, Chungnam National University School of Medicine, Daejeon, South Korea, ²Department of Internal Medicine, Chungnam National University School of Medicine, Daejeon, South Korea, ³Medicine, Eulji University Hospital, Daejeon, South Korea, ⁴Rheumatology, Eulji University Hospital, Daejeon, South Korea, ⁵Internal medicine, Chungnam National University School of Medicine, Daejeon, South Korea
Background/Purpose: Genetic factors provide over 90% of the overall susceptibility to ankylosing spondylitis (AS) and recent studies have focused on non-major histocompatibility complex genes. The…
Abstract Number: 981 • 2015 ACR/ARHP Annual Meeting
Anti-IL-17A Treatment Blocks Inflammation, Destruction and New Bone Formation in Experimental Spondyloarthritis in HLA-B27 Transgenic Rats
Melissa van Tok^1,2, Leonie van Duivenvoorde^1,3, Ina Kramer⁴, Peter Ingold⁴, Joel Taurog⁵, Frank Kolbinger⁴ and Dominique Baeten^1,2, ¹Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands, ²Department of Clinical Immunology and Rheumatology and Department of Experimental Immunology, Academic Medical Centre/University of Amsterdam, Amsterdam, Netherlands, ³Experimental Immunology, Department of Clinical Immunology and Rheumatology and Department of Experimental Immunology, Academic Medical Centre/University of Amsterdam, Amsterdam, Netherlands, ⁴Novartis Institutes for Biomedical Research, Basel, Switzerland, ⁵Internal Medicine, Rheumatic Diseases Division, UT Southwestern Medical Center, Dallas, TX
Background/Purpose: The IL-17 axis has been identified as a crucial pathophysiological pathway in spondyloarthritis (SpA). Targeting the IL-17 axis significantly suppressed inflammation and halted bone…
Abstract Number: 982 • 2015 ACR/ARHP Annual Meeting
CD4+CD146+ T Cells: The Primed IL-17 Secreting Cells in the Pathogenesis of Psoriatic Arthritis
Siba Raychaudhuri¹ and Smriti K. Raychaudhuri², ¹Med/Rheumatology, Univ California Davis/VA Sacramento, Davis, CA, ²Rheumatology/Immunology, VA Sacramento Medical Center, Davis, CA
Background/Purpose: CD146, also called melanoma cell adhesion molecule (MCAM), is a cell surface adhesion molecule. A small minority of the T cell population also express…
Abstract Number: 983 • 2015 ACR/ARHP Annual Meeting
ERAP1 Deficiency Protects HLA-B27 Transgenic Rats from Arthritis
Tri M. Tran¹, Sohee Hong², Tejpal Gill¹, Joshua Bennett¹, Keith Sikora¹ and Robert A. Colbert³, ¹NIAMS/NIH, Bethesda, MD, ²Bldg 10 Crc 10 Center Dr, NIAMS/NIH, Bethesda, MD, ³National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD
Background/Purpose: HLA-B27 (B27) confers a strong predisposition to spondyloarthritis (SpA), but accounts for < 25% of overall heritability of ankylosing spondylitis. Rats transgenic for HLA-B27…
Abstract Number: 984 • 2015 ACR/ARHP Annual Meeting
Tofacitinib Inhibits Inflammation and New Bone Formation in Murine Spondyloarthritis but Does Not Adversely Inhibit Normal Human MSC Function
Rik Lories¹, Katelijne De Wilde², Kerri Heritage¹, Richard Cuthbert³, Elena Jones³, Karlijn Debusschere⁴, Dennis McGonagle³ and Dirk Elewaut⁵, ¹Laboratory of Tissue Homeostasis and Disease, Skeletal Biology and Engineering Research Center, KU Leuven and University Hospitals Leuven., Leuven, Belgium, ²Laboratory for Molecular Immunology and Inflammation; Department of Rheumatology,, VIB, Ghent University and Ghent University Hospital, Ghent, Belgium, ³Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁴Laboratory for Molecular Immunology and Inflammation; Department of Rheumatology, VIB, Ghent University and Ghent University Hospital, Ghent, Belgium, ⁵Laboratory for Molecular Immunology and Inflammation, Department of Rheumatology, VIB, Ghent University and Ghent University Hospital, Ghent, Belgium
Background/Purpose: Inflammation and new bone formation at entheseal sites are hallmarks of spondyloarthritis (SpA). As TNF inhibition has only limited impact on new bone formation,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].